Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy
Authors
Keywords
-
Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 21, Pages 15716-15726
Publisher
American Chemical Society (ACS)
Online
2021-11-04
DOI
10.1021/acs.jmedchem.1c00961
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of Quantitative Relationship Between Target Expression and ADC Exposure Inside Cancer Cells
- (2020) Sharad Sharma et al. DRUG METABOLISM AND DISPOSITION
- Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade
- (2020) Liangliang Wang et al. Science Translational Medicine
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
- (2019) Yilun Wu et al. Frontiers in Immunology
- The function and dysfunction of memory CD8+ T cells in tumor immunity
- (2018) James L. Reading et al. IMMUNOLOGICAL REVIEWS
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Avelumab: A Review in Metastatic Merkel Cell Carcinoma
- (2018) Matt Shirley Targeted Oncology
- Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia
- (2018) Jeffrey Baron et al. Expert Review of Clinical Pharmacology
- Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
- (2018) Meghdad Abdollahpour-Alitappeh et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement
- (2017) Joong-Hyuk Sheen et al. JOURNAL OF IMMUNOLOGY
- Linkers Having a Crucial Role in Antibody–Drug Conjugates
- (2016) Jun Lu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
- (2016) Rong Deng et al. mAbs
- Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates
- (2016) Leanna R. Staben et al. Nature Chemistry
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
- (2015) Jessica R. McCombs et al. AAPS Journal
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
- (2015) Boris Shor et al. MOLECULAR IMMUNOLOGY
- Immune modulation for cancer therapy
- (2014) J Naidoo et al. BRITISH JOURNAL OF CANCER
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- The Human Papillomavirus Type 16 E5 Oncoprotein Inhibits Epidermal Growth Factor Trafficking Independently of Endosome Acidification
- (2010) Frank A. Suprynowicz et al. JOURNAL OF VIROLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
- (2008) Jagath R. Junutula et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started